Abstract
The genomics and proteomics sciences have fundamentally changed the ways in which drug targets are being identified, characterized and validated. Here we review how genomics and proteomics research is improving our understanding of genetic determinants of drug susceptibility and response and, conversely, how organic small molecules mediate their pharmacological effects by modulating genome and proteome activities. We also examine the effect this improved understanding has on the drug discovery and development process.
Keywords: Genomics, proteomics, pharmacogenetics, pharmacogenomics, chemical proteomics, drug resistance, activitybased protein profiling, yeast three-hybrid
3